Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling-Reference-Cited by-同舟云学术

Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling

Published:2020-02 Issue: Volume:13 Page:100115
ISSN:2468-1113
Container-title:Computational Toxicology
language:en
Short-container-title:Computational Toxicology

Author:

Pendse Salil N.,Efremenko Alina,Hack C. Eric,Moreau Marjory,Mallick Pankajini,Dzierlenga Michael,Nicolas Chantel I.,Yoon Miyoung,Clewell Harvey J.,McMullen Patrick D.

Publisher

Elsevier BV

Subject

Health, Toxicology and Mutagenesis,Computer Science Applications,Toxicology

Reference40 articles.

1. Quantitative interpretation of human biomonitoring data;Clewell;Toxicol. Appl. Pharmacol.,2008

2. Development and specification of physiologically based pharmacokinetic models for use in risk assessment;Clewell;Regul. Toxicol. Pharm.,2008

3. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment;Lipscomb;Adv. Exp. Med. Biol.,2012

4. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model;Clewell;Sci. Total Environ.,2001

5. Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation;Yoon;Toxicol. Res.,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PBPK model-based gender-specific risk assessment of N-nitrosodimethylamine (NDMA) using human biomonitoring data;Archives of Toxicology;2024-08-03

2. Physiologically based kinetic (PBK) modeling of propiconazole using a machine learning-enhanced read-across approach for interspecies extrapolation;Environment International;2024-07

3. Roadmap for action for advancing aggregate exposure to chemicals in the EU;EFSA Supporting Publications;2024-07

4. Development of a framework for risk assessment of dietary carcinogens;Food and Chemical Toxicology;2023-10

5. EFSA Pilot Project on New Approach Methodologies (NAMs) for Tebufenpyrad Risk Assessment. Part 1. Development of Physiologically‐Based Kinetic (PBK) Model Coupled With Pulmonary and Dermal Exposure;EFSA Supporting Publications;2023-01